Friends of Cancers Research | United States
Dr. Hillary S. Andrews, PhD, is a project leader and policy researcher whose scholarly output reflects strong engagement in cancer research regulation, patient-advocacy partnerships, and translational biomarker work. According to Google Scholar, she has an h-index of 7, with about 395 citations across her publications. She earned her PhD in Endocrinology and Animal Biosciences (Rutgers University, 2016), followed by a T32 NRSA postdoctoral fellowship in Tumor Biology at Georgetown University’s Lombardi Comprehensive Cancer Center. In her professional experience, she has held roles at Avalere Health (Consultant / FDA Fellow), then at Friends of Cancer Research, where she is now Director of Regulatory & Research Partnerships (since Dec 2022), after serving as Science Policy Analyst. Her work includes leading research partnerships like ctMoniTR and the HRD Harmonization Project, developing policy, authoring white-papers and peer-reviewed articles, and presenting findings at international meetings. Her research interests center on regulatory policy in oncology, translational biomarkers (e.g. HRD, circulating tumor DNA), patient access, market access pathways, and partnerships between patient advocates and researchers. Among her recognitions is authorship in high-visibility policy reports and scientific collaborations that bridge stakeholders (e.g. regulators, academia, patient advocates). In conclusion, her career demonstrates a consistent track record of integrating research, regulation, and stakeholder engagement to accelerate patient-centered cancer research and policy.
Profiles : Orcid | Google Scholar
Featured Publications
“Analysis of 20 Independently Performed Assays to Measure Homologous Recombination Deficiency (HRD) in Ovarian Cancer: Findings From the Friends’ HRD Harmonization Project”
“Advancing Evidence Generation for Circulating Tumor DNA: Lessons Learned from A Multi-Assay Study of Baseline Circulating Tumor DNA Levels across Cancer Types and Stages”
“An Analysis of Dosing-Related Postmarketing Requirements for Novel Oncology Drugs Approved by the U.S. Food and Drug Administration, 2012–2022”
“Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer”
“Sponsor Perspectives on the Impact of the COVID-19 Pandemic on Interventional Cancer Clinical Trial Protocols and Data Quality”